Insys Therapeutics Inc. (NASDAQ:INSY) had its target price cut by analysts at Royal Bank Of Canada from $32.00 to $26.00 in a research report issued on Thursday. The brokerage currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 95.93% from the company’s current price.

Other analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 9th. Piper Jaffray Cos. restated an “overweight” rating and set a $28.00 price objective on shares of Insys Therapeutics in a research note on Thursday, August 25th. Finally, Jefferies Group restated a “buy” rating and set a $22.00 price objective (up from $17.00) on shares of Insys Therapeutics in a research note on Thursday, August 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $23.67.

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Shares of Insys Therapeutics (NASDAQ:INSY) opened at 13.27 on Thursday. The company’s 50 day moving average is $15.76 and its 200-day moving average is $15.32. Insys Therapeutics has a 52 week low of $11.45 and a 52 week high of $33.88. The stock has a market capitalization of $950.07 million, a PE ratio of 19.98 and a beta of 1.93.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/royal-bank-of-canada-trims-insys-therapeutics-inc-insy-target-price-to-26-00.html

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.01. The business earned $67.10 million during the quarter, compared to the consensus estimate of $66.90 million. Insys Therapeutics had a return on equity of 20.08% and a net margin of 16.03%. The firm’s revenue was down 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.21 earnings per share. On average, equities analysts predict that Insys Therapeutics will post $0.39 earnings per share for the current year.

In other news, Director Theodore H. Stanley sold 15,000 shares of Insys Therapeutics stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $18.02, for a total value of $270,300.00. Following the completion of the sale, the director now directly owns 17,000 shares in the company, valued at $306,340. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel Brennan sold 5,781 shares of Insys Therapeutics stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $19.16, for a total transaction of $110,763.96. Following the completion of the sale, the vice president now owns 1 shares of the company’s stock, valued at $19.16. The disclosure for this sale can be found here. 69.20% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Freshford Capital Management LLC bought a new stake in shares of Insys Therapeutics during the second quarter worth approximately $6,159,000. American Century Companies Inc. raised its stake in shares of Insys Therapeutics by 1.9% in the second quarter. American Century Companies Inc. now owns 281,966 shares of the specialty pharmaceutical company’s stock worth $3,649,000 after buying an additional 5,154 shares in the last quarter. AHL Partners LLP bought a new stake in shares of Insys Therapeutics during the second quarter worth approximately $286,000. Folger Hill Asset Management LP raised its stake in shares of Insys Therapeutics by 11.4% in the second quarter. Folger Hill Asset Management LP now owns 1,597,945 shares of the specialty pharmaceutical company’s stock worth $20,677,000 after buying an additional 163,107 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Insys Therapeutics by 18.1% in the second quarter. Parametric Portfolio Associates LLC now owns 15,197 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 2,328 shares in the last quarter. Hedge funds and other institutional investors own 47.37% of the company’s stock.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

5 Day Chart for NASDAQ:INSY

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.